Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with VTC in Recurrent Ewing Sarcoma
NCT00516295Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2008
- Primary completion
- Aug 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in Ewing sarcoma, sponsored by National Cancer Institute. Started Feb 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT00516295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516295.